Tyra Biosciences to Present at Upcoming Investor Conferences

Rhea-AI Summary

Tyra Biosciences (NASDAQ: TYRA), a clinical-stage biotechnology company specializing in Fibroblast Growth Factor Receptor (FGFR) biology, has announced its participation in four major upcoming investor conferences in early 2025.

The company will participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference (February 11-12, virtual), the TD Cowen 45th Annual Healthcare Conference (March 3-5, Boston), the Jefferies Biotech on the Beach Summit (March 11-12, Miami), and the Barclays 27th Annual Global Healthcare Conference (March 11-13, Miami).

Management will engage in fireside chats and one-on-one investor meetings at most events, with presentations scheduled for February 12 at 2:00 PM ET (Oppenheimer), March 3 at 9:50 AM ET (TD Cowen), and March 12 at 8:30 AM ET (Barclays). Live and archived webcasts of the fireside chats will be accessible through TYRA's investor relations website.

News Market Reaction – TYRA

-0.74%

-0.74% Session move

In the trading session that priced this news, TYRA declined 0.74%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CARLSBAD, Calif., Feb. 11, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that company management will participate in the following investor conferences:

• Oppenheimer 35^th Annual Healthcare Life Sciences Conference, February 11-12, 2025
• Format: Fireside chat and one-on-one investor meetings
• Presentation Date/Time: Wednesday, February 12, 2025, at 2:00 PM ET
• Location: Virtual

• TD Cowen 45^th Annual Healthcare Conference, March 3-5, 2025
• Format: Fireside chat and one-on-one investor meetings
• Presentation Date/Time: Monday, March 3, 2025, at 9:50 AM ET
• Location: Boston

• Jefferies Biotech on the Beach Summit, March 11-12, 2025
• Format: One-on-one investor meetings
• Location: Miami

• Barclays 27^th Annual Global Healthcare Conference, March 11-13, 2025
• Format: Fireside chat and one-on-one investor meetings
• Presentation Date/Time: Wednesday, March 12, 2025, at 8:30 AM ET
• Location: Miami

A live and archived webcast of the fireside chats will be available via the For Investors page on the Investor section of the TYRA website. 

About Tyra Biosciences

Tyra Biosciences, Inc. (Nasdaq: TYRA) is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in FGFR biology. The Company's in-house precision medicine platform, SNÅP, enables rapid and precise drug design through iterative molecular SNÅPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. TYRA's expertise in FGFR biology has created a differentiated pipeline with three clinical-stage programs in targeted oncology and genetically defined conditions. The Company's lead precision medicine stemming from SNÅP, TYRA-300, is a potential first-in-class selective FGFR3 inhibitor that is designed to avoid the toxicities associated with inhibition of FGFR1, FGFR2 and FGFR4, while being agnostic for the FGFR3 gatekeeper mutations. TYRA-300 is expected to be evaluated in three Phase 2 studies: SURF302 for intermediate risk non-muscle invasive bladder cancer, BEACH301 for pediatric achondroplasia and SURF301 for metastatic urothelial cancer. TYRA is also developing TYRA-200, an oral, investigational, FGFR1/2/3 inhibitor, in the SURF201 study for metastatic intrahepatic cholangiocarcinoma, and TYRA-430, an oral, investigational FGFR4/3-biased inhibitor for FGF19⁺/FGFR4-driven cancers. TYRA is based in Carlsbad, CA. 

For more information about our science, pipeline and people, please visit www.tyra.bio and engage with us on LinkedIn.

Contact:

Amy Conrad
aconrad@tyra.bio

View original content to download multimedia:https://www.prnewswire.com/news-releases/tyra-biosciences-to-present-at-upcoming-investor-conferences-302373952.html

SOURCE Tyra Biosciences

FAQ

What investor conferences will TYRA attend in February and March 2025?

TYRA will attend four conferences: Oppenheimer Healthcare Life Sciences Conference (Feb 11-12), TD Cowen Healthcare Conference (March 3-5), Jefferies Biotech on the Beach Summit (March 11-12), and Barclays Global Healthcare Conference (March 11-13).

When is TYRA's presentation at the Oppenheimer Healthcare Conference 2025?

TYRA will present at the Oppenheimer Healthcare Conference on Wednesday, February 12, 2025, at 2:00 PM ET in a virtual format.

How can investors access TYRA's conference presentations in 2025?

Investors can access live and archived webcasts of TYRA's fireside chats through the For Investors page on the company's website.

What is the format of TYRA's participation in the 2025 investor conferences?

TYRA will participate through fireside chats and one-on-one investor meetings at most conferences, with the exception of the Jefferies summit which will only feature one-on-one meetings.

Where will TYRA's March 2025 conference presentations take place?

In March 2025, TYRA will present in Boston (TD Cowen Conference) and Miami (Jefferies Summit and Barclays Conference).